cGMP mediated smooth muscle vasodilators

28,283views

cGMP mediated smooth muscle vasodilators

IM EOR

IM EOR

Angina pectoris
Premature atrial contraction
Premature ventricular contraction
Supraventricular arrhythmias: Pathology review
Ventricular tachycardia
Ventricular fibrillation
Atrial flutter
Atrial fibrillation
Wolff-Parkinson-White syndrome
Atrioventricular nodal reentrant tachycardia (AVNRT)
Long QT syndrome and Torsade de pointes
Stable angina
Unstable angina
Prinzmetal angina
Class I antiarrhythmics: Sodium channel blockers
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
Heart failure
Diabetes mellitus
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Insulins
Diabetes insipidus
Hypercalcemia
Hypocalcemia
Hypernatremia
Hyponatremia
Hyperparathyroidism
Hypoparathyroidism
Hypercholesterolemia: Clinical
Lipid-lowering medications: Statins
Coronary artery disease: Clinical
Endocarditis
Class II antiarrhythmics: Beta blockers
Peptic ulcer
Acute pancreatitis
Chronic pancreatitis
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Gastritis
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
ECG cardiac infarction and ischemia
Abnormal heart sounds
Pulmonary valve disease
Tricuspid valve disease
cGMP mediated smooth muscle vasodilators
Sarcoidosis
Mycobacterium tuberculosis (Tuberculosis)
Pneumonia
Myocardial infarction
Adrenergic antagonists: Beta blockers
Hyperthyroidism
Hypothyroidism
Thyroid storm
Hypertension: Clinical
Class IV antiarrhythmics: Calcium channel blockers and others
Calcium channel blockers
Asthma
Emphysema
Pericarditis and pericardial effusion
Cardiac tamponade
Antiplatelet medications
Primary adrenal insufficiency
Pheochromocytoma
Cushing syndrome
Ischemic stroke
Bell palsy
Multiple sclerosis
Guillain-Barre syndrome
Bundle branch block
Migraine
Tension headache
Cluster headache
Syncope: Clinical
Transient ischemic attack
Non-steroidal anti-inflammatory drugs
Fibromyalgia
Gout
Systemic lupus erythematosus
Iron deficiency anemia
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Pulmonary hypertension
Pneumothorax
Lung cancer
Pulmonary embolism
Pseudomonas aeruginosa
Clostridium botulinum (Botulism)
Vitamin B12 deficiency
Influenza virus
Sickle cell disease (NORD)
Treponema pallidum (Syphilis)
Clostridium tetani (Tetanus)
Borrelia burgdorferi (Lyme disease)
Protein C deficiency
Folate (Vitamin B9) deficiency
Factor V Leiden
Protein S deficiency
Antithrombin III deficiency
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Paget disease of bone
Antiphospholipid syndrome
Rheumatoid arthritis
Ulcerative colitis
Candida
Cryptococcus neoformans
Positive and negative predictive value
Cirrhosis
Thyroid cancer
Shock
Neisseria gonorrhoeae
Pituitary adenoma
Seizures and epilepsy
Bordetella pertussis (Whooping cough)
Prostatitis
Meningitis
Vibrio cholerae (Cholera)
Testicular torsion
Epididymitis
Polycystic kidney disease
Polymyalgia rheumatica
Polymyositis
Hemorrhoid
Portal hypertension
Varicocele
Varicella zoster virus
Irritable bowel syndrome
Cytomegalovirus
Acid reducing medications
Concussion and traumatic brain injury
Hepatocellular carcinoma
Renal artery stenosis
Rheumatic heart disease
Cor pulmonale
Gastroesophageal reflux disease (GERD)
Sjogren syndrome
Huntington disease
Scleroderma
Acute cholecystitis
Viral hepatitis
Appendicitis
Diverticulosis and diverticulitis
Kidney stones
Acute pyelonephritis
Chronic pyelonephritis
Lower urinary tract infection
Glaucoma
Ascending cholangitis
Non-urothelial bladder cancers
Hydronephrosis
Celiac disease
Benign prostatic hyperplasia
Prerenal azotemia
Renal azotemia
Postrenal azotemia
Chronic kidney disease
Poststreptococcal glomerulonephritis
Membranous nephropathy
Membranoproliferative glomerulonephritis
IgA nephropathy (NORD)
Acute tubular necrosis
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Alport syndrome
Parkinson disease
Encephalitis
Delirium
Dementia with Lewy bodies
Vascular dementia
Frontotemporal dementia
Alzheimer disease
Adult brain tumors
Acid-base map and compensatory mechanisms
Erectile dysfunction
Acromegaly
Esophageal web
Esophageal disorders: Clinical
Colorectal cancer
Rapidly progressive glomerulonephritis
Goodpasture syndrome
Esophageal cancer
Gastric cancer
Esophagitis: Clinical
HIV (AIDS)
Anemia of chronic disease
Beta-thalassemia
Anemia of chronic disease
Alpha-thalassemia
Multiple myeloma
Shigella
Toxoplasma gondii (Toxoplasmosis)
Histoplasmosis
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Pneumonia: Clinical

Flashcards

cGMP mediated smooth muscle vasodilators

0 of 27 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 1 complete

USMLE® Step 2 style questions USMLE

0 of 7 complete

A 25-year-old woman, gravida 1, para 0, presents to the emergency department at 25 weeks gestation with a severe headache and epigastric pain for the past few hours. She has had no chronic problems, and her pregnancy was uneventful until now. She does not smoke or use alcohol or illicit drugs. Family history is noncontributory. Temperature is 37.33°C (99.2°F), pulse is 58/minute, respirations are 18/min, and blood pressure is 180/100 mm Hg. On physical examination, the patient is uncomfortable and has mild epigastric tenderness. 3+ pitting edema is present in bilateral legs. Fetal heart sounds are normal. Dipstick urine shows 3+ protein. After stabilization, which medications should be administered for blood pressure control in this patient?  

Transcript

Watch video only

cGMP-mediated smooth muscle vasodilators, as their name implies, are medications that promote dilation of blood vessels by potentiating the effect of cyclic guanosine monophosphate, or cGMP for short. These medications are mainly used to treat hypertension, heart failure, and angina pectoris, which is a pain caused by reduced blood flow to the heart muscle. All right, first, let’s focus on the structure of blood vessels. Blood vessels have three layers, also called “tunics,” or coverings, that surround the vessel lumen, which is the hollow part of the vessel that contains the blood. The innermost tunic is the tunica intima, which includes the endothelial cells; the next one is the tunica media, or middle tunic, which is mostly made of smooth muscle cells and sheets of elastin protein; and finally, there’s the tunica externa, or outside tunic, which is made up of loosely woven fibers of collagen. Moreover, the tunica media can contract, causing vasoconstriction, where the lumen gets a lot smaller; or it can relax, or vasodilate, causing the lumen’s diameter to increase, allowing for more blood flow.

Now, within endothelial cells of the tunica intima, there’s an enzyme called nitric oxide synthase, which uses the amino acid L-arginine and molecular oxygen to synthesize nitric oxide or NO for short. Once synthesized, nitric oxide diffuses to adjacent smooth muscle cells in the tunica media, where it binds and activates an enzyme guanylyl cyclase. This enzyme converts guanosine triphosphate, GTP, into cyclic guanosine monophosphate, cGMP, which is a second messenger that induces relaxation of smooth muscle cells in vessel walls. All right, now moving on to pharmacology. cGMP-mediated smooth muscle vasodilators are subdivided into two main groups: antianginal medications, which are used to treat anginal pain, when oxygen delivery to the heart is inadequate for normal heart function; and antihypertensive medications, which are used to treat high blood pressure.

First, let’s start with antianginal medications, also known as nitrates. These medications are actually prodrugs, meaning that they need to be converted into their active form, called nitric oxide, before they can produce the desired effect. Once converted, nitric oxide diffuses to surrounding smooth muscle cells and stimulates guanylyl cyclase, thereby increasing the concentration of cGMP. Ultimately, this results in vasodilation of both veins and arteries. But, even though they affect both, nitrates dilate veins and venules more than they dilate arteries and arterioles. Moreover, vasodilation of small veins and venules result in peripheral pooling of the blood and decreased return of the venous blood to the heart. This way nitrates predominantly reduce preload, which is the volume of blood that the heart must eject with each contraction. On the other hand, vasodilation of small arteries and arterioles lowers the systemic vascular resistance, so nitrates will also reduce afterload, which is the pressure that the heart must work against to eject the blood. Ultimately, by reducing preload and afterload, nitrates reduce the amount of work the heart has to do, and eventually decreasing the heart’s oxygen consumption; but, at the same time, they increase oxygen delivery to heart tissue by dilating coronary arteries to a small degree.

Common medications in this class include nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate (which is the active metabolite of isosorbide dinitrate). Nitroglycerin can be administered sublingually, intravenously, or transdermally. The sublingual form of nitroglycerin has a rapid onset, causing a vasodilatory effect within the first 3 minutes after administration that lasts approximately up to 25 minutes. This makes sublingual nitroglycerin useful for the treatment and short-term prevention of an acute anginal pain. On the other hand, intravenous nitroglycerin is reserved for individuals who don't respond to sublingual nitroglycerin; while transdermal nitroglycerin is indicated for the long-term prevention of angina pectoris. In contrast to nitroglycerin, isosorbide dinitrate and isosorbide mononitrate are taken peroraly, but they have a longer onset of action of 15-30 minutes and duration of action of 6-10 hours, which makes them useful for the long-term prevention of angina pectoris.

Common side effects of nitrates include flushing, headache, orthostatic hypotension, and reflex tachycardia, which is treated by co-administration of beta blockers. Interestingly enough, workers in the construction and demolition industries who are regularly exposure to nitroglycerin or isosorbide dinitrate at their job can develop “Monday disease.” This is characterized by building up tolerance throughout the workweek and then losing that tolerance during the weekend. When they re-expose themselves to the nitrates the following monday, they experience tachycardia, dizziness, and headaches until they develop tolerance again. It’s important to note that nitrates are contraindicated in individuals with right ventricular infarction, since they’re very sensitive to changes in the preload, therefore they can easily develop severe hypotension. As far as drug interactions go, nitrates should not be combined with medications that are used to treat erectile dysfunction, like sildenafil, tadalafil, or vardenafil. These medications block the enzyme phosphodiesterase 5, which converts cGMP into its inactive form, GMP. So if taken together, it results in an accumulation of cGMP that can’t be inactivated, which may lead to a precipitous fall in blood pressure, myocardial infarction, and even death.

Now switching gears and moving on to antihypertensive medications - hydralazine and nitroprusside. First, let’s focus on hydralazine which works by increasing the level of cGMP in smooth muscle cells, but the mechanism is not fully understood. However, unlike nitrates, hydralazine dilates arteries and arterioles more than it dilates veins, thereby predominantly reducing afterload. Now for indications, intravenous hydralazine is used to treat acute hypertensive emergencies, like preeclampsia or hypertension in pregnancy; while oral hydralazine is used to treat chronic hypertension, when other antihypertensive medications are not effective. In addition, hydralazine in combination with nitrates can be used for the treatment of chronic heart failure. For side effects, hydralazine causes flushing, headache, edema, angina, and reflex tachycardia, so it should be given with beta blockers and avoided in individuals with coronary artery disease. It’s important to note that hydralazine can cause an autoimmune-like condition called drug-induced systemic lupus erythematosus. Finally, individuals who break down certain medicines at a very slow rate, known as slow acetylators, might experience hydralazine toxicity due to an accumulation of this medication in their body.

Key Takeaways

cGMP, or cyclic guanosine monophosphate, is a second messenger that mediates smooth muscle relaxation in response to various vasoactive agents such as nitric oxide (NO). cGMP-mediated smooth muscle vasodilators, are drugs that promote vasodilation by increasing the effect of cGMP. These drugs include hydralazine and nitroprusside, used to treat hypertension, and nitrates used to treat angina pectoris.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Hurst's the Heart, 14th Edition: Two Volume Set" McGraw-Hill Education / Medical (2017)
  5. "Formation of Nitric Oxide by Aldehyde Dehydrogenase-2 Is Necessary and Sufficient for Vascular Bioactivation of Nitroglycerin" Journal of Biological Chemistry (2016)
  6. "Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA" American Journal of Physiology-Gastrointestinal and Liver Physiology (2003)